Vaccines: latest news

Vaccines resources

  • Vaccines

    HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection....

    From: Preventing HIV

    Information level Level 4
  • Vaccines

    The promise of an effective HIV vaccine has always been just over the horizon, but more than 20 years after the identification of HIV, vaccines...

    From: HIV transmission & testing

    Information level Level 4

Vaccines features

Vaccines news from aidsmap

  • Targets proliferate in HIV cure research

    The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and this one featured a more varied range of experimental approaches than ever in the search for ways of eliminating ...

    21 July 2015 | Gus Cairns
  • New drug holds out promise of long-term control or even cure of HIV

    Scientists at the Scripps Research Institute in California have discovered a new type of drug that may permanently inhibit HIV from becoming reactivated in the cells that are chronically infected with it. The new drug, didehydro-cortistatin A (dCA), appears ...

    18 July 2015 | Gus Cairns
  • One step further towards an HIV vaccine: and this one performed as expected

    A recent experimental HIV vaccine protected 50% of a group of twelve rhesus monkeys from infection by Simian Immunodeficiency Virus (SIV). Furthermore, it did so by providing so-called ‘sterilising immunity’, meaning that it completely prevented infection in these monkeys ...

    14 July 2015 | Gus Cairns
  • We may need to combine many approaches to achieve a cure, delegates hear

    It is unlikely that one single approach will achieve a cure for HIV infection, delegates at a community cure workshop held the day before the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, heard last ...

    09 March 2015 | Gus Cairns
  • Elite controllers may pay a high price for their low viral load

    About one in 200 people with HIV maintains an undetectable viral load and high CD4 counts without having to take antiretroviral therapy (ART). These so-called ‘elite controllers’ have long been the targets of research into how their immune ...

    07 January 2015 | Gus Cairns
  • Groundbreaking HIV vaccine's effects were real – and could be made to work better

    Findings from further studies using a reformulation of the only HIV vaccine that has ever worked in a large efficacy trial were presented at the recent HIV Research for Prevention conference (HIVR4P). They showed evidence of stronger antibody responses, ...

    13 November 2014 | Gus Cairns
  • Research for Prevention conference opens with real hope for an HIV vaccine

    “There’s only one Berlin patient still. But by this time next year he will at least be joined by 40-50 Portland monkeys.” This was vaccine researcher Louis Picker, summarising in quotable form why the outlook for the development of an ...

    29 October 2014 | Gus Cairns
  • Novel immune-suppressant vaccine completely blocks HIV infection in monkeys: human trials planned

    A novel and relatively simple vaccine that can be administered orally has managed to completely block rectal infection with SIV, the monkey equivalent of HIV, in rhesus macaques and produced rapid re-suppression of viral load in monkeys who were ...

    26 August 2014 | Gus Cairns
  • Vaccine trials – where next?

    New efficacy trials of HIV vaccines based on what has been learned in the RV144 vaccine trial in Thailand and the HVTN 505 trial in the US are going forward in heterosexual people in South Africa and will probably also ...

    16 October 2013 | Gus Cairns
  • Unravelling the mystery of the vaccine trials

    There have been thousands of small vaccine trials in the history of HIV – the first one took place in 1986 – but only six large efficacy trials, and the results of these have been puzzling. Many presentations ...

    11 October 2013 | Gus Cairns
More news

Vaccines news selected from other sources

  • AIDS pioneer finally brings AIDS vaccine to clinic

    Human trials of more than 100 different AIDS vaccines have taken place since researchers proved in 1984 that HIV caused the disease. Robert Gallo, whose U.S. National Cancer Institute laboratory published the four landmark papers in Science that convinced the world of the link between this recently discovered retrovirus and the growing epidemic, has closely monitored—and often sharply critiqued—the AIDS vaccine search since it began. But Gallo, who now runs the Institute of Human Virology (IHV) in Baltimore, Maryland, has always been a spectator—until today.

    14 October 2015 | Science Insider
  • Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

    HIV Prevention Research & Development Funding Trends 2000–2014: Investment Priorities To Fund Innovation In An Evolving Global Health And Development Landscape is the 11th annual report by the Working Group, a collaboration among AVAC, UNAIDS, and the International AIDS Vaccine Initiative (IAVI). The report summarizes investment in HIV prevention research across eight prevention options, as well as HSV-2 vaccine and HIV cure and therapeutic vaccine R&D.

    19 July 2015 | AVAC
  • Bold goal of stopping HIV is motivating great science

    The massive challenge of finding an HIV vaccine has unleashed stunning creativity in laboratories all over the world. While we work toward the long-term goal of a vaccine, we are also pulling in partners from many sectors to improve prevention, treatment, and access to options in the short term.

    13 July 2015 | Devex
  • J&J vaccine completely prevented HIV in half of monkeys in trial

    An experimental Johnson & Johnson vaccine completely prevented HIV infection in half of monkeys that got the shot and then were exposed to high doses of an aggressive virus, results that spurred the company to test the vaccine in people, academic and company researchers said on Thursday.

    03 July 2015 | Reuters
  • Potential New HIV Therapy Seen in Component of Immune Cells

    A research team led by Weill Cornell Medical College scientists has discovered a way to limit replication of the most common form of HIV at a key moment when the infection is just starting to develop. The study, published June 25 in Nature Communications, has shed light on a potential new element of human immunity against HIV-1 and could provide a powerful new strategy — perhaps as part of an HIV vaccine — to limit the severity of the disease.

    26 June 2015 | Weill Cornell Medical College
  • NIAID-funded HIV vaccine research generates key antibodies in animal models

    A trio of studies being published today in the journals Science and Cell describes advances toward the development of an HIV vaccine. The three study teams all demonstrated techniques for stimulating animal cells to produce antibodies that either could stop HIV from infecting human cells in the laboratory or had the potential to evolve into such antibodies. Each of the research teams received funding from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

    19 June 2015 | Eurekalert Medicine & Health
  • Sequential immunizations could be the key to HIV vaccine

    Scientists have thought for some time that multiple immunizations, each tailored to specific stages of the immune response, could be used to generate a special class of HIV-fighting antibodies, so-called broadly neutralizing antibodies. New findings provide the first evidence supporting this approach.

    19 June 2015 | Science Daily
  • French Based Biosantech Reports HIV Vaccine Safe

    Researchers from French-based Biosantech Company today reported that the company’s HIV vaccine candidate is not toxic to 48 HIV-positive patients enrolled in a double-blind study taking place in France. The data was presented at the International Conference on Retroviruses and Novel Drugs in suburban Chicago.

    17 June 2015 | PR Web
  • Some chimpanzees infected with AIDS virus may harbor protective, humanlike gene

    When Peter Parham’s postdoc first showed him data suggesting a gene in some wild chimpanzees infected with the AIDS virus closely resembled one that protects humans from HIV, he was skeptical.

    29 May 2015 | Science
  • HIV immunity: rare gene differences offer hope for treatment

    Seven years after the ‘Berlin patient’ was cured of HIV, scientists are looking to natural immunity through genetic variation to create vaccine and gene therapies

    12 May 2015 | The Guardian
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.